Company news

Jazz Pharmaceuticals plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023

February 14, 2023

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

January 18, 2023

Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

December 20, 2022

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

December 4, 2022

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

November 27, 2022

Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)

November 17, 2022

Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

November 8, 2022

Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research

November 2, 2022

Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022

October 25, 2022

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

October 18, 2022

Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022

September 14, 2022

Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures

August 17, 2022

Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance

August 2, 2022

Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022

July 19, 2022

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity

June 27, 2022

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

June 6, 2022

Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine

May 31, 2022

Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference

May 31, 2022

Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings

May 11, 2022

Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics

May 8, 2022

Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance

May 3, 2022

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist

May 3, 2022

Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference

May 2, 2022

Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022

April 19, 2022

Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types

April 7, 2022

Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule

April 6, 2022

Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences

March 28, 2022

Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics

March 27, 2022

Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing

March 24, 2022

Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors

March 23, 2022

Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting

March 7, 2022

JAZZ Pharmaceuticals announces full year and fourth quarter 2021 financial results

February 28, 2022

Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022

February 14, 2022

Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule

February 1, 2022

Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader

January 9, 2022

Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

January 4, 2022

U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

January 2, 2022

Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder

December 29, 2021

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor

December 14, 2021

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer

December 12, 2021

Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting

December 11, 2021

Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting

November 30, 2021

Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer

November 29, 2021

Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance

November 8, 2021

Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting

November 3, 2021

Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021

October 25, 2021

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

September 12, 2021

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

August 11, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.